文献速递眼底病与葡萄膜炎

英国年龄相关性黄斑变性研究补充剂成本效益:结合临床试验与真实世界结局数据

Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data.
PubMed 文献 · Br J Ophthalmol · 2017-08-23

研究基于英国国家医疗服务体系(NHS)视角,构建患者水平健康状态转换模型,评估年龄相关性眼病研究(AREDS)1和2补充剂对双侧中期年龄相关性黄斑变性(AREDS 3类)或单侧新生血管性年龄相关性黄斑变性(AREDS 4类)患者的成本效益。模型使用AREDS数据及包含92 976例雷珠单抗治疗事件的前瞻性多中心全国nAMD数据库研究真实世界结局与资源使用数据。结果显示AREDS 3类增量成本效益比为30 197英镑;AREDS 4类补充剂较无干预更有效(10.59 vs 10.43 QALYs)且成本更低(52 074 vs 54 900英镑)。

要点

  • AREDS 3类患者补充剂的增量成本效益比为30 197英镑。
  • AREDS 4类患者补充剂较无干预更有效(10.59 vs 10.43 QALYs)且成本更低(52 074 vs 54 900英镑)。
  • 作者认为AREDS 4类患者启动补充剂应纳入公共卫生政策考虑。

核心结论

  • 对AREDS 3类患者公开资助补充剂取决于医疗系统支付意愿;对AREDS 4类患者启动补充剂既节省成本又更有效,应纳入公共卫生政策考虑。

研究设计与样本

  • 基于更好眼视力水平构建患者水平健康状态转换模型,模拟服用AREDS维生素补充剂的成本与结局,设置英国国家医疗服务体系(NHS)。
  • 模型数据来自AREDS及一项包含92 976例雷珠单抗治疗事件的前瞻性多中心全国nAMD数据库研究的真实世界结局与资源使用。
  • 比较立即干预使用AREDS补充剂与不使用补充剂两种策略,计算质量调整生命年(QALYs)和医疗成本及终生增量成本与QALYs,并采用单因素和概率敏感性分析检验模型不确定性。

主要发现

  • AREDS 3类的增量成本效益比为30 197英镑。
  • AREDS 4类与无干预相比,AREDS补充剂更有效(10.59 vs 10.43 QALYs)且成本更低(52 074 vs 54 900英镑),为患者终生数据。

关键数值与推荐

  • AREDS 3类增量成本效益比:30 197英镑。
  • AREDS 4类QALYs:补充剂10.59 vs 无干预10.43。
  • AREDS 4类成本:补充剂52 074英镑 vs 无干预54 900英镑。

临床怎么用

  • 作者认为AREDS 4类患者启动AREDS补充剂既节省成本又更有效,应纳入公共卫生政策考虑。
  • 对AREDS 3类患者公开资助补充剂取决于医疗系统支付意愿。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To evaluate the cost-effectiveness of Age-Related Eye Disease Study (AREDS) 1 & 2 supplements in patients with either bilateral intermediate age-related macular degeneration, AREDS category 3, or unilateral neovascular age-related macular degeneration AMD (nAMD), AREDS category 4. METHODS: A patient-level health state transition model based on levels of visual acuity in the better-seeing eye was constructed to simulate the costs and consequences of patients taking AREDS vitamin supplements. SETTING: UK National Health Service (NHS). The model was populated with data from AREDS and real-world outcomes and resource use from a prospective multicentre national nAMD database study containing 92 976 ranibizumab treatment episodes. INTERVENTIONS: Two treatment approaches were compared: immediate intervention with AREDS supplements or no supplements. MAIN OUTCOME MEASURES: quality-adjusted life years (QALYs) and healthcare costs were accrued for each strategy, and incremental costs and QALYs were calculated for the lifetime of the patient. One-way and probabilistic sensitivity analyses were employed to test the uncertainty of the model. RESULTS: For AREDS category 3, the incremental cost-effectiveness ratio was £30 197. For AREDS category 4 compared with no intervention, AREDS supplements are more effective (10.59 vs 10.43 QALYs) and less costly (£52 074 vs 54 900) over the lifetime of the patient. CONCLUSIONS: The recommendation to publicly fund AREDS supplements to category 3 patients would depend on the healthcare system willingness to pay. In contrast, initiating AREDS supplements in AREDS category 4 patients is both cost saving and more effective than no supplement use and should therefore be considered in public health policy.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Lee AY, Butt T, Chew E, et al. Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data. Br J Ophthalmol. 2017. PMID: 28835423. doi:10.1136/bjophthalmol-2017-310939

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。